Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $82.15, marking a +0.72% move from the previous day.

CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know

Intellia Therapeutics

Beam Therapeutics

Editas Medicine

2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year.

Top 5 Moonshots for 2022 Countdown: My No. 5 Pick

Amedisys

Altice USA

Chegg

Frontdoor Inc.

Open Lending Corp

Pan American Silver

Royal Philips

Pinterest

StoneCo

If you're looking for bargain stocks to buy that are down 30% or more in 2021, that's not an easy task. Here are 10 that fit the bill.

10 Bargain Stocks to Buy After Falling 30% in 2021

CRISPR Therapeutics is a gene therapy company pioneering the CRISPR/Cas9 gene editing tool, discovered by its scientific co-founder. The company is partnered with Vertex - a $58bn market cap biotech with >$6bn in cash - on its lead program in Sickle Cell Disease.

Crispr Therapeutics: Buy The Dip On Promise Of Vertex Collaboration

Investors need to pay close attention to CRISPR Therapeutics (CRSP) stock based on the movements in the options market lately.

Implied Volatility Surging for CRISPR Therapeutics (CRSP) Stock Options

The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, reached an all-time high of $210 in January of this year before a gradual decline drove the stock price down over 60% to its current level of around $80.

What's Happening With CRISPR Stock?

Don't let the downtrend in CRSP stock fool you; the company is still making headway in advancing potentially life-changing therapeutics. The post CRISPR Therapeutics Is One of Today's Best Biotech Value Investments appeared first on InvestorPlace.

CRISPR Therapeutics Is One of Today's Best Biotech Value Investments

The gene-editing specialist's share price is now down roughly 54% in 2021.

Why CRISPR Therapeutics Stock Sank 12.5% in November

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock?

CRISPR Therapeutics AG (CRSP) Down 17.4% Since Last Earnings Report: Can It Rebound?

CRISPR Therapeutics AG's (CRSP) CEO Sam Kulkarni at Piper Sandler 33rd Annual Virtual Healthcare Conference (Transcript)

One of the company's co-founders won a Nobel prize in chemistry for her work done on the CRISPR technology.

Crispr Therapeutics: An Interesting Company That Has Reconnected With A Fair Valuation

Evercore

CRISPR Therapeutics' (CRSP) CEO Samarth Kulkarni on 4th Annual Evercore ISI HealthCONx Conference

The FDA grants a Regenerative Medicine Advanced Therapy designation to CRISPR Therapeutics' (CRSP) CTX110 targeting CD19+ B-cell malignancies.

CRISPR's (CRSP) CAR-T Cell Therapy Gets FDA's RMAT Designation

CRISPR Therapeutics AG is a pre-revenue company specializing in CRISPR-Cas9. It allows accurate genetic replacement of the disease-associated DNA. CTX001 is the treatment candidate for Sickle Cell Disease and Beta-Thalassemia from the collaboration between CRSP and Vertex Pharmaceuticals Incorporated.

CRISPR's Life-Saving Technology Has Massive Potential

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110™, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies.

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies

CRISPR gene editing is promising, but there's a risk that it can cause unwanted mutations.

Do CRISPR Therapeutics and Intellia Face a Big Safety Risk?

Vertex Pharmaceuticals

The companies are collaborating on a potential blockbuster.

Better Buy: Vertex Pharmaceuticals vs. CRISPR

CRISPR Therapeutics (CRSP) receives clearance from Health Canada to initiate clinical studies for VCTX210, its investigational therapy for the treatment of type 1 diabetes.

CRISPR (CRSP) to Begin Clinical Study on Diabetes Therapy Drug

-Initiation of patient enrollment expected by year-end- -Initiation of patient enrollment expected by year-end-

CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes

CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies. The post Being First Is Not Enough For Crispr Therapeutics appeared first on InvestorPlace.

Being First Is Not Enough For Crispr Therapeutics

The gene-editing specialist's stock is now down roughly 37% year to date.

Why CRISPR Therapeutics Stock Fell 18.4% in October

CRISPR Therapeutics (CRSP) reports narrower-than-expected Q3 loss. Yet, revenues miss estimates for the third quarter of 2021.

CRISPR Therapeutics (CRSP) Q3 Earnings Beat, Revenues Lag

Vertex, Inc.

Vertex plans to develop gene-editing therapies with Mammoth Biosciences.

Why Vertex Is Striking Another Gene-Editing Deal With a Company Not Named CRISPR Therapeutics

-Achieved target enrollment in CTX001 clinical trials for beta thalassemia (TDT) and sickle cell disease (SCD); regulatory submissions planned for late 2022-

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results

Intercept Pharma

Ligand Pharmaceuticals

Novavax

Vaxart

Based on analysts' loftiest price targets, these drugmakers could double to nearly quintuple investors' money over the next 12 months.

News for CRISPR Therapeutics Stock (CRSP)